13,337 Shares in Johnson & Johnson $JNJ Purchased by Greg Jennings LLC

Key Points

• Greg Jennings LLC purchased 13,337 Johnson & Johnson shares worth approximately $3.53 million in the third quarter, making JNJ its 15th-largest holding at 2.4% of assets. Institutional investors collectively own 69.55% of the company.
• Johnson & Johnson insiders sold 64,515 shares valued at roughly $17.27 million over the past 90 days, while executives Timothy Schmid and Jennifer Taubert reported significant individual sales.
• Analysts maintain a generally positive outlook, with the stock carrying a “Moderate Buy” consensus and an average target of $275.92. J&J also exceeded quarterly EPS expectations, reported 5.9% year-over-year revenue growth, and declared a quarterly dividend of $1.34 per share.

Greg Jennings LLC purchased a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 13,337 shares of the company's stock, valued at approximately $3,531,000. Johnson & Johnson accounts for approximately 2.4% of Greg Jennings LLC's holdings, making the stock its 15th largest holding.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. Abel Hall LLC lifted its stake in Johnson & Johnson by 2.0% in the third quarter. Abel Hall LLC now owns 9,341 shares of the company's stock valued at $2,473,000 after buying an additional 183 shares during the last quarter. Crown Wealth Group LLC grew its position in shares of Johnson & Johnson by 2.0% during the third quarter. Crown Wealth Group LLC now owns 2,791 shares of the company's stock worth $739,000 after acquiring an additional 55 shares during the last quarter. James Hambro & Partners LLP grew its position in shares of Johnson & Johnson by 51.3% during the third quarter. James Hambro & Partners LLP now owns 2,534 shares of the company's stock worth $671,000 after acquiring an additional 859 shares during the last quarter. Washburn Capital Management Inc. acquired a new position in shares of Johnson & Johnson in the 3rd quarter valued at $1,101,000. Finally, Prairie Advisory LLC increased its holdings in shares of Johnson & Johnson by 100.2% in the 3rd quarter. Prairie Advisory LLC now owns 3,382 shares of the company's stock valued at $896,000 after acquiring an additional 1,693 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insider Buying and Selling

In related news, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the transaction, the executive vice president directly owned 25,447 shares of the company's stock, valued at $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Jennifer Taubert sold 15,000 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the transaction, the executive vice president directly owned 194,451 shares of the company's stock, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 64,515 shares of company stock valued at $17,271,766 over the last ninety days. Corporate insiders own 0.16% of the company's stock.

Analyst Ratings Changes

Several analysts recently commented on the stock. Bank of America reiterated a "neutral" rating and issued a $278.00 price target on shares of Johnson & Johnson in a research report on Tuesday, September 29th. Weiss Ratings raised shares of Johnson & Johnson from a "buy (b)" rating to a "buy (b+)" rating in a research report on Thursday, October 8th. Royal Bank Of Canada dropped their price objective on shares of Johnson & Johnson from $290.00 to $280.00 and set an "outperform" rating on the stock in a research note on Wednesday, October 14th. The Goldman Sachs Group restated a "buy" rating and issued a $282.00 price objective on shares of Johnson & Johnson in a research note on Thursday, July 16th. Finally, Johnson Rice reaffirmed a "buy" rating on shares of Johnson & Johnson in a report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average target price of $275.92.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: MedTech launch supports growth: J&J introduced the next-generation Shockwave C2 Aero Fly coronary intravascular lithotripsy catheter in the U.S. The device delivers pulses at 2 Hz and is designed to reduce treatment time for calcified coronary lesions, potentially improving physician adoption and strengthening J&J’s cardiovascular portfolio. J&J launches Shockwave C2 Aero Fly catheter
• Positive Sentiment: Pipeline data remains constructive: TREMFYA maintained or improved remission in Crohn’s disease patients with perianal fistulas through 48 weeks, supporting the drug’s potential expansion and helping offset concerns about future competition to older products. J&J TREMFYA Crohn’s disease data
• Positive Sentiment: Supportive analyst view: TD Cowen reiterated a Buy rating and $300 price target, citing underappreciated pharmaceutical and MedTech growth. J&J’s latest quarterly results also exceeded EPS and revenue expectations, providing a favorable earnings backdrop.
• Neutral Sentiment: Acquisition strategy under review: Analysts see growing sales from acquired heart technologies and a larger hospital network, but competition, development costs and the need to convert revenue growth into stronger ownership returns remain concerns. J&J medical device deals analysis
• Negative Sentiment: Competitive and valuation risks: Rapport reported positive Phase II results for a novel oral bipolar drug licensed from J&J, potentially creating a future competitor to J&J’s Caplyta. Separately, JLPascual downgraded J&J to Sell, while commentary highlights that the stock trades at a premium multiple and must sustain earnings growth to justify it.

Johnson & Johnson Trading Up 2.2%

Shares of JNJ stock opened at $259.42 on Wednesday. The company has a market capitalization of $625.17 billion, a P/E ratio of 23.83, a price-to-earnings-growth ratio of 2.51 and a beta of 0.21. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The business's 50 day moving average is $265.53 and its two-hundred day moving average is $249.84. Johnson & Johnson has a twelve month low of $184.66 and a twelve month high of $281.07.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.54% and a net margin of 16.20%. The business had revenue of $25.40 billion during the quarter, compared to analysts' expectations of $25.38 billion. During the same quarter in the prior year, the business earned $2.80 earnings per share. The company's quarterly revenue was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities analysts forecast that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a $1.34 dividend. This represents a $5.36 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson's payout ratio is currently 81.21%.

About Johnson & Johnson

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.